INTRODUCTION
Phosphatidylinositol 3-kinase (PI3-kinase) pathway signaling promotes cell growth, proliferation, and survival by several mechanisms (see Figure S1 available online for a schematic; Wullschleger et al., 2006; Yuan and Cantley, 2008) . Receptor tyrosine kinases and other signaling pathways activate PI3-kinase, which generates phosphatidylinositol-3,4,5-trisphosphate (PIP3) (Yuan and Cantley, 2008) . PIP3 activates Akt, which promotes cell growth, proliferation, and survival by phosphorylating diverse substrates (Manning and Cantley, 2007) , including the tuberous sclerosis complex (TSC) (Inoki et al., 2002) . Phosphorylation by Akt negatively regulates TSC, leading to the activation of the mammalian target of rapamycin (mTOR) kinase (Inoki et al., 2002) . mTOR functions in two distinct complexes, mTORC1, which is directly inhibited by rapamycin, and mTORC2, which can be indirectly inhibited by rapamycin (Guertin and Sabatini, 2007; Sarbassov et al., 2006) . mTORC1 promotes cell growth and proliferation by activating S6 kinase and inactivating 4EBP1, promoting protein synthesis (Inoki et al., 2002) . mTORC2 regulates Akt activation (Guertin and Sabatini, 2007) . PI3-kinase signaling is attenuated by Pten, which dephosphorylates PIP3 (Maehama and Dixon, 1998) , reducing the activation of Akt, mTORC1, and S6 kinase. As a result, Pten deficiency increases the growth, proliferation, and survival of many cells (Sun et al., 1999) , and Pten is commonly deleted in diverse cancers (Di Cristofano and Pandolfi, 2000) .
PI3-kinase pathway signaling has divergent effects on stem cells. Conditional deletion of Pten from embryonic stem cells and neural stem cells increases cell cycle entry and self-renewal (Gregorian et al., 2009; Groszer et al., 2001 Groszer et al., , 2006 Sun et al., 1999) . In contrast, Pten deletion from adult HSCs increases cell cycle entry but this leads to rapid HSC depletion (Yilmaz et al., 2006; Zhang et al., 2006) . We showed that this depletion was mediated by mTOR activation as rapamycin blocked the depletion of Pten-deficient HSCs (Yilmaz et al., 2006) . Subsequent studies of Tsc1-deficient HSCs confirmed that increased PI3-kinase pathway signaling can drive HSCs into cycle but that this leads to mTOR-mediated HSC depletion (Chen et al., 2008; Gan et al., 2008) . Pml deletion also increased HSC cycling and led to mTOR-mediated HSC depletion (Ito et al., 2008) . mTOR is thus a critical modulator of stem cell maintenance, raising the question of how mTOR activation leads to stem cell depletion.
While Pten deletion leads to the depletion of normal HSCs, this leads to the generation and expansion of leukemia-initiating cells (Yilmaz et al., 2006) . This makes it possible to deplete leukemiainitiating cells while rescuing normal HSC function via rapamycin in mice that are deficient for Pten. A sophisticated understanding of PI3-kinase pathway signaling can therefore lead to therapies that eliminate cancer-initiating cells with limited toxicity to normal stem cells.
One mechanism by which Pten deletion and PI3-kinase pathway activation could deplete stem cells involves a tumor suppressor response. Sustained oncogenic signals can induce tumor suppressors that cause cellular senescence (Lin et al., 1998; Serrano et al., 1997) . Conditional inactivation of Pten in prostate leads to the induction of p53-mediated senescence, impeding the development of prostate cancer (Chen et al., 2005) . These studies raise the question of whether a similar tumor suppressor response occurs after Pten deletion in stem cells and whether this suppresses leukemogenesis or depletes HSCs.
Another mechanism by which Pten deletion could deplete HSCs involves the inactivation of FoxO family transcription factors. When localized to the nucleus, FoxO transcription factors promote the expression of enzymes that eliminate reactive oxygen species (ROS). However, activated Akt phosphorylates FoxO proteins, leading to their retention in the cytoplasm (Biggs et al., 1999; Brunet et al., 1999) and increasing ROS levels. HSCs are particularly sensitive to the toxic effects of ROS (Ito et al., 2004 (Ito et al., , 2006 . Deletion of FoxO1/3/4 or FoxO3a alone from adult HSCs leads to increased ROS levels and HSC depletion that can be at least partially rescued by the antioxidant N-acetyl-cysteine (NAC) (Miyamoto et al., 2007; Tothova et al., 2007; Yalcin et al., 2008) . The depletion of Tsc1-deficient HSCs is also partly rescued by NAC treatment (Chen et al., 2008) . On the other hand, constitutively active Akt did not increase ROS levels in HSCs and the depletion of these HSCs could not be rescued by NAC treatment (Kharas et al., 2010) . These results raise the question of whether Pten deficiency and FoxO deficiency deplete HSCs by similar or different mechanisms.
We found that Pten deficiency and FoxO1/3/4 deficiency lead to HSC depletion by different mechanisms. We were unable to detect FoxO3a inactivation or a significant increase in ROS levels in HSCs after Pten deletion. We were not able to rescue the depletion of Pten-deficient HSCs by treating with NAC. Instead, Pten deletion induced the expression of p16
Ink4a and p53 in (Figures 1A and 1B; Christensen and Weissman, 2001; Kiel et al., 2005) . The increase in Akt phosphorylation after rapamycin treatment is consistent with the attenuation of a negative feedback loop from S6 kinase to IRS-1 as a result of reduced mTORC1 activation (Harrington et al., 2004 (Kiel et al., 2005) were sorted from control and Ptendeleted mice and stimulated with SCF and TPO in culture for 24 hr, they showed an overall decrease in FoxO3a staining as well as decreased nuclear staining and increased cytoplasmic staining ( Figure S3 ). In contrast, when HSCs were stained immediately after isolation from mice, we detected no change in FoxO3a expression or subcellular localization after Pten deletion ( Figures 1F-1H ): FoxO3a continued to localize to the nucleus. mTORC1 activity was clearly elevated after Pten deletion based on increased phospho-S6 levels in freshly isolated bone marrow cells and HSCs (Figures 1A, 1B, 1D, 1E, and 1H) . This increase in phospho-S6 levels was attenuated by rapamycin treatment ( Figures 1A and 1B) . These changes were further confirmed by increased phospho-4EBP1 levels in bone marrow cells after Pten deletion ( Figure 1A ). This increase in phospho-4EBP1 levels was also attenuated by rapamycin treatment ( Figure 1A ). Thus, Pten deletion increased mTORC1 and S6 kinase activation in a manner that was reversed by rapamycin, suggesting that the changes that lead to HSC depletion after Pten deletion are mediated by this branch of the PI3-kinase pathway.
Pten Deletion Increases ROS Levels in Thymocytes but Not in HSCs or Bone Marrow Cells
We assessed the intracellular levels of ROS in CD150 Figures 2D and 2F ). Only mice showing no signs of neoplasms were used in these experiments. The increase in ROS levels in the thymus after Pten deletion was attenuated by daily subcutaneous injection of the antioxidant NAC, but NAC did not affect ROS levels in bone marrow cells, HSCs, or MPPs ( Figure 2F ). It is unclear why Pten deletion increased ROS levels in thymocytes but not in HSCs or WBM cells, but ROS regulation is known to differ among hematopoietic cells (Ito et al., 2004 (Ito et al., , 2006 Tothova et al., 2007) . We were also unable to detect significant effects of Pten deletion on the expression of FoxO target genes (Tothova et al., 2007) or antioxidant response genes in bone marrow cells, HSCs, or MPPs ( Figures S4C-S2H ).
NAC Does Not Rescue Major Hematopoietic Defects after Pten Deletion
Consistent with the normal ROS levels in HSCs and most other hematopoietic cells, daily treatment with NAC for 3 weeks after pIpC treatment did not rescue the changes in spleen, thymus, or bone marrow cellularity after Pten deletion ( Figures S4A and  S4B ). NAC treatment also did not rescue the depletion of bone marrow HSCs (Figures 2G and 2J) . MPP frequency and number in the bone marrow and spleen were not significantly affected by Pten deletion or NAC treatment ( Figures 2H, 2I , 2K, and 2L). The frequency and absolute number of HSCs and MPPs increased significantly in the spleen 3 weeks after pIpC treatment (Figures 2I and 2L) , consistent with the extramedullary hematopoiesis that arises after Pten deletion (Yilmaz et al., 2006) . NAC attenuated the increase in splenic HSCs, though HSC frequency and number still increased significantly in the spleen (Figures 2I and 2L) . NAC also had little effect on other changes in hematopoiesis after Pten deletion ( Figures  S5A-S5C ). The inability of NAC to rescue hematopoietic defects after Pten deletion contrasts with the ability of rapamycin to do so (Yilmaz et al., 2006 of control cells all survived for 120 days and showed no signs of leukemogenesis (n = 20, Figure 3F ). In contrast, all 20 recipients of Pten-deleted bone marrow died with myeloproliferative disease (MPD) and/or T cell acute lymphoblastic leukemia (T-ALL) 33 to 112 days after pIpC treatment, irrespective of whether they were treated with NAC ( Figure 3F ; Figures S5D-S5I ). NAC treatment did not significantly affect the lifespan of mice after Pten deletion ( Figure 3F ) in contrast to rapamycin, which prevents leukemogenesis and extends the lifespan of Ptendeleted mice (Yilmaz et al., 2006) .
Pten Deletion Leads to a Tumor Suppressor Response in HSCs
We tested whether Pten deletion induced a tumor suppressor response by assessing the expression of p16 Ink4a , p19 Arf , p53, and p21 Cip1 in splenocytes. We did not detect p16 Ink4a protein expression in splenocytes with or without Pten deletion (Figure 4A) . We did detect very low levels of p16 Ink4a transcript in splenocytes, but transcript levels were not significantly affected by Pten deletion or rapamycin treatment ( Figure S6A ). In contrast, we observed clear increases in p19
Arf , p53, and p21
Cip1 protein after Pten deletion ( Figure 4A ). These increases were attenuated or eliminated by rapamycin, suggesting that the expression of these tumor suppressors was elevated as a consequence of mTOR activation (Figure 4A) . We confirmed significantly increased expression of p19 Arf ( Figure 4B) and p21 Cip1 ( Figure S6B ) by qPCR in Pten-deficient splenocytes and that these increases were eliminated by rapamycin treatment. We observed no effect of Pten deletion or rapamycin treatment on p53 transcript levels ( Figure S6C ), consistent with the observation that p53 expression is mainly regulated posttranscriptionally (Olsson et al., 2007) .
We hypothesized that this tumor suppressor response inhibited leukemogenesis but promoted the depletion of HSCs after Pten deletion and that rapamycin rescued HSC depletion by attenuating the tumor suppressor response in HSCs. Figure 4D ). We were unable to detect a clear increase in p19 Arf expression after Pten deletion ( Figure 4D ). We also stained CD150 more quickly, 27 to 65 days after ending pIpC treatment (Figure 5A ). Histology confirmed that the mice had MPD and/or histiocytic sarcoma and/or T-ALL when they died. These data indicate that deficiency for p16 Ink4a and p19 Arf accelerates leukemogenesis after Pten deletion.
To better understand the relative contributions of p16 Ink4a and p19
Arf to the suppression of leukemogenesis after Pten deletion, we performed the same experiment with mice that were compound mutants for Pten and p16 Ink4a ( Figure 5C ) or Pten and p19 Arf ( Figure 5B ). p16 Ink4a deficiency did not significantly affect the rate at which mice died or the spectrum of hematopoietic neoplasms that arose after pIpC treatment ( Figure 5C ). In contrast, p19 Arf deficiency did significantly (p < 0.02) increase the rate at which mice died after pIpC treatment ( Figure 5B ). These results suggest that p19 Arf suppresses leukemogenesis after Pten deletion, consistent with the increase in p19 Arf expression in splenocytes after Pten deletion ( Figure 4A ). Arf were used as negative and positive controls. To assess the role of p53, we performed the same experiment with mice that were compound mutant for Pten and p53 (Figure 5D) Figure 5D ). All mice were confirmed to have MPD, AML, and/or T-ALL when they died ( Figure 5D ). These results suggest that p53 suppresses leukemogenesis after Pten deletion. Figure 6 into irradiated wildtype recipient mice, along with a radioprotective dose of 300,000 recipient bone marrow cells. The HSCs were isolated from the donor mice after they had been treated with three injections of pIpC over 6 days. p16 Ink4a deficiency prolonged the reconstituting capacity of Pten-deficient HSCs. Wild-type and p16 Ink4a -deficient HSCs gave long-term multilineage reconstitution by donor cells in all recipient mice ( Figure 6A ). In contrast, Pten-deleted (Pten fl/fl Mx-1-Cre + ) HSCs only gave transient multilineage reconstitution for 6 to 8 weeks after transplantation, consistent with our prior study (Yilmaz et al., 2006) . ). Data are from 3 independent experiments with a total of 9 mice/ genotype except for compound mutant mice, which had 14-20 mice/genotype. increased the opportunity for leukemogenesis by prolonging the reconstituting capacity of Pten-deleted HSCs. These data might also reflect a limited role for p16
Ink4a in the suppression of leuke- Compound mutant mice that died had MPD, T-ALL, and/or histiocytic sarcoma at the time of death. All data are from 3 independent experiments with a total of 7-17 recipients per treatment. (E-H) Mice were transplanted with mutant HSCs as described above then sacrificed 8 weeks later to assess the frequency of donor CD150 (Table S1 ).
See also Figure S7 and Table S1 .
long-term multilineage reconstitution by donor cells in all recipient mice for at least 16 weeks whereas Pten-deleted (Pten fl/fl Mx-1-Cre + ) HSCs gave transient multilineage reconstitution for 4 to 6 weeks after transplantation ( Figure 6D) (for up to 12 weeks, p < 0.002; Figure 6D ), with significantly higher donor cell reconstitution levels than from Pten fl/fl Mx-1-Cre + HSCs ( Figure 6D ). In a separate experiment, we confirmed that donor HSCs ( Figure 6F ) and MPPs ( Figure 6H ) could be recovered 8 weeks after transplantation of 10 Pten fl/fl Mx-1-Cre + p53 À/À HSCs but not after transplantation of 10 Pten fl/fl Mx-1-Cre + HSCs. p53 therefore contributes to the depletion of Pten-deficient HSCs in addition to suppressing leukemogenesis, consistent with its increased expression after Pten deletion in splenocytes and HSCs (Figure 4 ). The precise mechanisms by which p16 Ink4a and p53 promote the depletion of HSCs after Pten deletion are uncertain. We did not detect any effect of Pten deletion or rapamycin treatment on the frequency of whole bone marrow cells or HSCs undergoing cell death ( Figure S7A ) or expressing senescence-associated b-galactosidase ( Figures S7C-S7E ). Indeed, we observed an increase in the frequency of dividing HSCs after Pten deletion (rather than a decrease as would be expected if senescence were occurring), and this increase was rescued by rapamycin treatment ( Figure S7B ). These results suggest that increased p16 Ink4a and p53 expression in dividing HSCs is incompatible with HSC maintenance, perhaps because these tumor suppressors promote maturation out of the stem cell pool.
Pten-Deficient Leukemias Have Mutations that Attenuate the Tumor Suppressor Response
To test whether Pten-deficient leukemias acquire secondary mutations that attenuate the tumor suppressor response, we tested whether there was a selection pressure to inactive p53 in these leukemias. The tumor suppressors could be attenuated by many mechanisms that would silence or inactivate the tumor suppressors or other genes in the same pathways. Because it would be impossible to test all such mechanisms, we circumvented this problem by studying leukemogenesis in a sensitized, p53 heterozygous background. If there is selective pressure to inactivate p53 in Pten-deficient leukemias, leukemias should arise more quickly from p53 +/À mice as compared to p53 +/+ mice, and we would expect the leukemias to delete the wildtype p53 allele. Young adult wild-type, p53 Figure 7A ). Heterozygosity for p53 therefore accelerates leukemogenesis. We next examined p53 expression in the thymus of mice that developed leukemias. In each case, the thymus was enlarged, completely effaced, and appeared to consist mainly of leukemic lymphoblasts. Figure 7C ). Thus, Pten deletion induces a strong selective pressure to inactivate the tumor suppressor response in leukemogenic cells.
DISCUSSION
Pten deletion increased Akt, mTORC1, and S6 kinase activation in HSCs (Figures 1B, 1D , and 1E) but we could find no evidence for reduced FoxO1 or FoxO3a expression or cytoplasmic sequestration ( Figures 1B and 1F-1H ; Figure S2 ). We observed a clear increase in ROS levels within thymocytes after Pten deletion but not in HSCs (Figure 2 ). Consistent with this, NAC treatment attenuated the increase in ROS levels in thymocytes but did not rescue the changes in hematopoiesis, HSC frequency (Figure 2 ), or HSC reconstituting capacity ( Figure 3A) after Pten deletion. This contrasted with results from FoxO1/3/4-deficient mice in which ROS levels clearly increased within HSCs and NAC treatment at least partially rescued HSC depletion (Tothova et al., 2007) . Pten deletion and FoxO1/3/4 deletion thus lead to the depletion of HSCs by different mechanisms. HSC depletion after Pten deletion is mediated largely by mTOR activation with no evidence so far for an important contribution by oxidative stress.
Pten deletion induced a tumor suppressor response in hematopoietic cells, characterized by increased expression of p19 Arf and p53 in splenocytes (Figures 4A and 4B) Figure 5C ). This suggests that hematopoietic cells mainly rely upon the p53 pathway to suppress leukemogenesis after Pten deletion. This is consistent with results from mouse prostate in which Pten deletion induces p53-dependent senescence (Chen et al., 2005) . Interestingly, this senescence response is p19 Arf independent in prostate (Chen et al., 2009) Pten deletion imposes a strong selection against the tumor suppressor response (Figure 7 ). It is also important to note that we do not know which hematopoietic cells are transformed after Pten deletion. Therefore, the tumor suppressors may act in HSCs themselves to suppress leukemogenesis or they may act in downstream cells. Although p16 Ink4a and p19 Arf are both encoded at the Cdkn2a locus, they are regulated by different promoters, have no sequence homology, and have different molecular functions (Sherr, 2001) . The mechanisms by which Pten deletion or other oncogenic stimuli induce these tumor suppressor expressions are not understood. Although it is well established that oncogenic stresses such as c-Myc or E1A expression also activate the p19 Arf -p53 pathway (de Stanchina et al., 1998; Zindy et al., 1998) , the mechanisms behind this activation remain unclear. The mechanisms behind p16
Ink4a and p53 activation in response to Ras activation also remain unknown (Serrano et al., 1997) . The best-characterized consequences of p53 or p16 Ink4a activation are senescence and apoptosis. However, these responses have been characterized only in certain non-stem cell populations, and it is possible that p53 or p16 Ink4a activation may have other effects on stem cells. We did not detect any evidence that hematopoietic cells underwent senescence or cell death after Pten deletion ( Figure S7 ). However, HSCs are asynchronously depleted over a 4 to 8 week period after Pten deletion ( Figure 6 ). This raises the formal possibility that HSCs asynchronously undergo cell death or senescence over 4 to 8 weeks, such that very few HSCs express markers of cell death or senescence at any single time point, rendering it undetectable. Nonetheless, the simplest interpretation of our data is that p16 Ink4a and p53 (Akala et al., 2008; Kiel et al., 2008) . These tumor suppressors thus play a physiological role promoting the transition from HSCs to MPPs and negatively regulating the selfrenewal potential of multipotent cells. Increased expression of p16 Ink4a and p53 in dividing HSCs after Pten deletion may accelerate the normal maturation of cells out of the HSC pool, leading to HSC depletion. The ability to rescue the hematopoietic phenotypes in Ptendeficient mice with rapamycin suggests that these phenotypes are driven by mTORC1 activation. However, our data indicate only that increased mTORC1 activation is required for HSC depletion and leukemogenesis, not that it is sufficient. This may explain why other genetic backgrounds that activate mTORC1, such as Tsc1 deletion (Chen et al., 2008; Gan et al., 2008) , do not necessarily lead to leukemogenesis. mTORC1-independent pathways downstream of Pten presumably also contribute to leukemogenesis. Because rapamycin can indirectly inhibit mTORC2 in addition to mTORC1 (Sarbassov et al., 2006) and mTORC2 is required for the development of prostate cancer after Pten deletion (Guertin et al., 2009) of Pten-deficient hematopoietic stem/progenitor cells would be unlikely to have the opportunity to acquire secondary mutations before being depleted and therefore would be unlikely to progress to leukemia. Leukemias may be more likely to hyperactivate the PI3-kinase pathway by other types of mutations that are better tolerated by hematopoietic cells. Additional studies of the PI3-kinase pathway in stem cells will provide additional insights into stem cell regulation and the development of cancer.
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EXPERIMENTAL PROCEDURES
Mice C57BL/Ka-Thy-1.1 (CD45.2) and C57BL/Ka-Thy-1.2 (CD45.1) mice were used in hematopoietic reconstitution experiments. Mx-1-Cre + mice (Kuhn et al., 1995) , Pten fl/fl mice (Groszer et al., 2001) , Ink4a +/À mice (Sharpless et al., 2001) , Arf +/À mice (Kamijo et al., 1997) , Ink4a/Arf +/À mice (Serrano et al., 1996) , and p53 +/À mice (Jacks et al., 1994) were backcrossed for at least 10 generations onto a C57BL/Ka background. All mice were housed in the Unit for Laboratory Animal Medicine at the University of Michigan. All animal procedures were reviewed and approved by the University of Michigan Committee on the Use and Care of Animals.
pIpC, Rapamycin, and N-Acetyl-L-Cysteine Administration Polyinosine-polycytidine (pIpC) and rapamycin were administered as previously described (Yilmaz et al., 2006) . In brief, pIpC from Sigma (St. Louis, MO) or from Amersham (Piscataway, NJ) was resuspended in Dulbecco's phosphate-buffered saline (D-PBS) at 2 mg/ml (for Sigma) or 50 mg/ml (for Amersham), and mice were injected intraperitoneally (i.p.) with 25 mg/gram (for Sigma) or 0.5 mg/gram (for Amersham) of body mass every other day for 6-14 days. Rapamycin (LC Laboratories, Woburn, MA) was dissolved in absolute ethanol at 10 mg/ml and diluted in 5% Tween-80 (Sigma) and 5% PEG-400 (Hampton Research, Aliso Viejo, CA) before being administered daily by i.p. injection at a dose of 4 mg/kg. N-Acetyl-L-cysteine (NAC; Sigma) was administered daily by subcutaneous injection at 100 mg/kg (pH 7.0) starting 1 day after the final dose of pIpC.
Flow Cytometry and HSC Isolation
Bone marrow cells were obtained by crushing the long bones (tibias and femurs), pelvic bones, and vertebrae in a mortar and pestle with Hank's buffered salt solution without calcium or magnesium, supplemented with 2% heat-inactivated calf serum (GIBCO, Grand Island, NY; HBSS+). Cells were triturated and filtered through nylon screen (45 mm, Sefar America, Kansas City, MO) to obtain a single-cell suspension. For isolation of c-kit + Flk2 marrow cells were incubated with PE-conjugated anti-CD150 (TC15-12F12.2; BioLegend, San Diego, CA), FITC-conjugated anti-CD48 (HM48-1; BioLegend), FITC-conjugated anti-CD41 (MWReg30; BD PharMingen, San Diego, CA), APC-conjugated anti-Sca-1 (Ly6A/E; E13-6.7), and biotin-conjugated anti-c-kit (2B8) antibody, in addition to antibodies against the following FITC-conjugated lineage markers: CD2 (RM2-5), B220 (6B2), CD3 (KT31.1), CD5 (53-7.3), CD8 (53-6.7), Gr-1 (8C5), and Ter119 (TER-119). Biotin-conjugated c-kit was visualized with streptavidin-conjugated APC-Cy7. HSCs were sometimes pre-enriched by selecting c-kit + cells with paramagnetic anti-biotin microbeads and autoMACS (Miltenyi Biotec, Auburn, CA). Dead cells were excluded with the viability dye 4 0 ,6-diamidino-2-phenylindole (DAPI) (1 mg/ml).
To measure ROS levels, bone marrow cells were isolated and stained as above except that the HSC stain was modified to make the FITC channel available for DCFDA (2 0 -7 0 -dichlorofluorescein diacetate, Molecular Probes, Eugene, OR) staining. Antibodies for HSC isolation were as described above except for the following antibodies: PE/Cy5-conjugated anti-CD150 (TC15-12F12.2; BioLegend), PE-conjugated anti-CD48 (HM48-1; BioLegend), PEconjugated anti-CD41 (MWReg30; BD PharMingen), and PE-conjugated antibodies against lineage markers. After antibody staining, thymus cells, whole bone marrow cells, or c-kit + enriched cells were incubated with 5 mM DCFDA for 15 min at 37 C followed by flow cytometry.
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